News | February 02, 2026
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Subscribe To Our Newsletter & Stay Updated
